METHODS FOR TREATING EYE DISORDERS

• US 20100098727A1
• Filed: 12/28/2009
• Published: 04/22/2010
• Est. Priority Date: 05/20/2003
• Status: Abandoned Application

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: FIRST, ERIC R.
• Application Number:
  US12/648,260
• Publication Number:
  US 20100098727A1
• Time in Patent Office: Days
• US Class Current: 424/239.1
• CPC Class Codes: A61K 38/4893 Botulinum neurotoxin (3.4.24.69)
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/02 Immunomodulators

Abstract

Methods of treating an eye disorder are disclosed. Particular methods comprise a step of locally administering a Clostridial toxin to the eye of a patient to treat the disorder.

Claims

1. A method for treating eye inflammation in a patient in need thereof, the method comprising the steps of administering a Clostridial toxin in an amount effective to treat eye inflammation, thereby treating the eye inflammation.

2. The method of claim 1 wherein eye inflammation is a result of bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, or inflammation response after intra-ocular lens implantation.

3. The method of claim 1 wherein the eye inflammation is a result of conjunctivitis.

4. The method of claim 1 wherein the Clostridial toxin is administered topically to the eye.

5. The method of claim 1 wherein the Clostridial toxin is produced by Clostridial beratti, Clostridia butyricum, Clostridial tetani bacterium or Clostridial botulinum.

6. The method of claim 1 wherein Clostridial toxin is a botulinum toxin selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F, G and mixtures thereof.

7. The method of claim 1 wherein the Clostridial toxin is botulinum toxin type A.

8. The method of claim 1 wherein the Clostridial toxin is administered in conjunction with a vasoconstrictor.

9. The method of claim 1 wherein the Clostridial toxin is administered in conjunction with a polyanionic component.

10. A method for treating edema of the eye in a patient in need thereof, the method comprising the step of administering a botulinum toxin in an amount effective to treat edema of the eye in the patient, thereby treating the edema of the eye.

11. The method of claim 10, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C₁, D, E, F or G.

12. The method of claim 10, wherein the edema of the eye is macular edema.

13. The method of claim 10, wherein the botulinum toxin is botulinum toxin type A and is administered in and amount from about 0.01 U/kg (units of botulinum toxin per kilogram of patient weight) to about 15 U/kg.

14. The method of claim 10, wherein the botulinum toxin is applied topically.